This readout from JASMINE represents the first positive randomized controlled trial of an investigational FcRn blocker in active SLE.² Based on these results, Johnson & Johnson has initiated enrollment in the phase 3 GARDENIA study (NCT07438496) of adults with active SLE.¹
SLE is a chronic, systemic autoimmune disease in which pathogenic IgG autoantibodies drive inflammation and tissue injury across multiple organ systems, including the skin, joints, kidneys, heart, lungs, and central nervous system.¹ The treatment landscape, while expanding, remains limited relative to disease heterogeneity. Hydroxychloroquine is a cornerstone of SLE management.³ Among approved biologics, belimumab (Benlysta), an anti-BLyS antibody, and anifrolumab (Saphnelo), a type I interferon receptor antagonist, are the two agents with specific FDA approval for SLE, with current ACR/EULAR guidance positioning both as first-line biologic options for moderate to high disease activity.⁴˒⁵ Voclosporin is approved specifically for lupus nephritis. Rituximab is used off-label in refractory cases.⁵ Despite these options, many patients remain on chronic glucocorticoids, with attendant risks of infection, osteoporosis, cardiovascular disease, and metabolic complications. An agent capable of reducing disease activity while enabling steroid tapering would address a recognized gap across the SLE population.
Mechanism of Action and Drug-Class Background
Nipocalimab is a fully human IgG1 monoclonal antibody that binds the neonatal Fc receptor (FcRn) with high affinity, blocking IgG recycling and thereby reducing circulating IgG levels, including the pathogenic autoantibodies that contribute centrally to SLE and other autoantibody-driven diseases, while leaving IgM, IgA, and complement-mediated functions intact.¹ This selective mechanism distinguishes it from broader immunosuppressive approaches and from agents targeting upstream immune pathways such as B-cell survival or interferon signaling.
Key Facts
Drug name and class: Nipocalimab; neonatal Fc receptor (FcRn)-blocking monoclonal antibody (investigational in SLE; not approved)
Indication under investigation: Active systemic lupus erythematosus in adults
Regulatory action: FDA Fast Track designation (January 2026); fifth Fast Track designation for nipocalimab
Supporting trial: JASMINE (NCT04882878), phase 2b — 52-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging; n=228
Primary efficacy outcome: Statistically significant SRI-4 composite response at week 24 vs placebo
Secondary efficacy signals: Multiple secondary/exploratory endpoints met, including steroid-sparing potential; full data pending publication
Safety: No new safety signals; profile consistent with prior phase 2 studies (granular AE data not yet published)
Next step: Phase 3 GARDENIA study (NCT07438496) actively enrolling; full JASMINE data pending conference presentation
Approved indication: Generalized myasthenia gravis in adults and patients ≥12 years (as IMAAVY; FDA approval April 2025)
The FcRn inhibitor class also includes efgartigimod (Vyvgart; argenx), approved for generalized myasthenia gravis (gMG) and under evaluation in lupus nephritis, and rozanolixizumab (Rystiggo; UCB), approved for gMG. Nipocalimab differs from efgartigimod in that it is a full-length monoclonal antibody rather than an engineered Fc fragment, a distinction the developer argues may have implications for placental FcRn blockade in maternal-fetal indications.5
The SLE Fast Track designation is nipocalimab's fifth from the FDA, following prior designations for hemolytic disease of the fetus and newborn (HDFN), warm autoimmune hemolytic anemia, gMG, fetal and neonatal alloimmune thrombocytopenia (FNAIT), and Sjögren's disease.¹ The agent also holds Breakthrough Therapy designation for HDFN and Sjögren's disease. In April 2025, nipocalimab received FDA approval under the brand name IMAAVY for gMG in adults and pediatric patients aged 12 years and older, supported by data from the phase 3 VIVACITY-MG3 trial.6
Outstanding questions include the optimal nipocalimab dose for phase 3 advancement, the durability of SRI-4 response through week 52, the clinical magnitude and practical feasibility of glucocorticoid tapering, and the long-term safety profile of sustained FcRn blockade and attendant IgG reduction.
References
Johnson & Johnson. Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus. Press release. March 3, 2026. https://www.jnj.com/media-center/press-releases
Gatto M, Zen M, Cruciani C, Iaccarino L, Doria A. Navigating the landscape of SLE treatment: an expert viewpoint on the rationality and limitations of early biologic intervention. Autoimmun Rev. 2024;23(10):103612. https://doi.org/10.1016/j.autrev.2024.103612
Ząbczyńska M, Sobczyk M, Krawczyk-Ożóg A, et al. Advances in targeted therapy for systemic lupus erythematosus: current treatments and novel approaches. Int J Mol Sci. 2025;26(3):929. https://doi.org/10.3390/ijms26030929